30th Annual North American Cystic Fibrosis Conference

W18: NT: Biomarkers to Evaluate Treatment

Oct 28, 2016 2:00pm ‐ Oct 28, 2016 3:30pm

Standard: $49.99

Description

The discovery of biomarkers that track with the correction of CFTR and/or disease progression can address many of the present goals of transforming patient care. For example, ex vivo markers such as primary cell organoid or monolayer responses to therapies that modulate CFTR function can help us enhance personalization of care and allow us to tailor CFTR modulator therapy based on patient cell responses to drug. In patients, markers of CFTR correction such as sweat chloride are being standardized, and markers of disease progression and/or manifestations such as inflammation are under study. The session will highlight a number of approaches to biomarker discovery and application to foster a discussion of the questions we can answer using this approach to improve care.

Educational Objectives:
  • Summarize about innovative approaches to identify novel biomarkers that are associated with markers of disease progression in CF.
  • Identify the most promising biomarkers to sensitively detect the biologic activity of new therapeutics and enable CF drug development.
  • Define the role of biomarkers in therapeutic drug development and the need for appropriate studies that will enable qualification and validation.

*** This session was streamed live during the 2016 NACFC. To watch free archived versions of the live streamed sessions, register here: https://arc.nacfconference.org/cff/live/16

Chair(s):

Speaker(s):

You must be logged in and own this session in order to post comments.